The CASNMMI annual meeting took place at Hyatt Regency Toronto on June 9, 2024 during the SNMMI 2024 Annual Meeting (June 8-11, 2024 Toronto, Canada).
Lifetime Achievement Awards (LTAA)
Professor Jixiao Ma (马寄晓教授)
Professor Jixiao Ma, born in 1926, a native of Nanjing Jiangsu Province. He is one of the first - generation of nuclear medicine professionals, nuclear medicine expert in China, and the winner of the “China Nuclear Medicine Physician Lifetime Achievement Award” 2013. In 1958, Professor Ma founded the department of Nuclear Medicine of Shanghai Sixth People’s Hospital, opened the first radionuclide therapy ward 1962, and became the first one reporting the clinical study of 131I renal imaging, successful translated 131I-6-I-cholesterol into diagnosis agent of adrenal cortical diseases, which was awarded as the Shanghai Major Science and Technology Achievement Award in 1978. In 1993, he established the Osteoporosis Department and served as the dept director for more than 30 years at Shanghai Sixth People’s Hospital. Over more than 70 years of his Nuclear Medicine career journey, Prof. Ma published more than 200 scientific journal papers and multiple text-book editions. He was a member of the Nuclear Medicine Expert Advisory Committee of the Ministry of Health, a former editorial expert of the "Chinese Journal of Nuclear Medicine and Molecular Imaging", deputy editor-in-chief of the "Shanghai Imaging Journal", and a member of the International Society of Bone Density. Up to 2019, Prof. Ma still accepted patients at Sixth People's Hospital. Currently, Prof. Ma still dedicates his time to the field of Nuclear Medicine by online teaching “马寄晓核医学教室”. Congratulations to Prof. Jixiao Ma receiving 2024 CASNMMI Lifetime Achievement Award!!!!
Congratulations to all Young Investigator Award (YIA) winners!
1st Prize: Ivan E. Wang, University of Michigan, Department of Radiology.
Cyclotron Produced Gallium-68 to Manufacture Clinical Gallium-68 Tracers Without Commercial Kits.
2nd Prize: Xinrui Ma, University of North Carolina at Chapel Hill, Biomedical Research Imaging Center.
Development of Copper-64, Cobalt-55 and Gallium-68 Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Cancer Diagnostic and Therapeutic Applications: Adjusting In Vivo Distribution using Multi-Amine Macrocycles.
2nd Prize: Jiarou Wang, Peking Union Medical College Hospital, Beijing China.
Safety, Maximum Tolerated Dose, and Patient-Specific Dosimetry of [177Lu]Lu-LNC1011 in metastatic Castration-Resistant Prostate Cancer Patients.
3rd Prize: Xuejun Wen, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore.
Development of dual targeting heterodimer 177Lu LNC1009 for cancer theranostics.
3rd Prize: Huidong Xie, Yale University.
Dose-aware diffusion model for 3D low-dose PET denoising: A multi-institutional validation with reader study and real low- dose data.
3rd Prize: Ruiyue Zhao, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Determining the simplified quantification method of [18F]AlF-P16-093 for patients with primary prostate cancer.